J
Jörn Lötsch
Researcher at Goethe University Frankfurt
Publications - 323
Citations - 13745
Jörn Lötsch is an academic researcher from Goethe University Frankfurt. The author has contributed to research in topics: Opioid & Morphine. The author has an hindex of 65, co-authored 308 publications receiving 12418 citations. Previous affiliations of Jörn Lötsch include Norwegian University of Science and Technology & University of Göttingen.
Papers
More filters
Journal ArticleDOI
GTP cyclohydrolase and tetrahydrobiopterin regulate pain sensitivity and persistence
Irmgard Tegeder,Michael Costigan,Robert S. Griffin,Andrea Abele,Inna Belfer,Helmut Schmidt,Corina Ehnert,Jemiel Nejim,Jemiel Nejim,Claudiu Marian,Joachim Scholz,Tianxia Wu,Andrew Allchorne,Luda Diatchenko,Alexander M. Binshtok,David Goldman,Jan Adolph,Swetha Sama,Steven J. Atlas,William A. Carlezon,Aram Parsegian,Jörn Lötsch,Roger B. Fillingim,William Maixner,Gerd Geisslinger,Mitchell B. Max,Clifford J. Woolf +26 more
TL;DR: It is reported that GTP cyclohydrolase (GCH1), the rate-limiting enzyme for tetrahydrobiopterin (BH4) synthesis, is a key modulator of peripheral neuropathic and inflammatory pain.
Journal ArticleDOI
Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication.
Julia Kirchheiner,Helmut Schmidt,Mladen V. Tzvetkov,J-T H A Keulen,Jörn Lötsch,Ivar Roots,Jürgen Brockmöller +6 more
TL;DR: CYP2D6 genotypes predicting ultrarapid metabolism resulted in about 50% higher plasma concentrations of morphine and its glucuronides compared with the EM, and it might be good if physicians would know about the CYP2D 6 duplication genotype of their patients before administering codeine.
Journal ArticleDOI
Ziconotide for treatment of severe chronic pain
TL;DR: An overview of the benefits and limitations of intrathecal ziconotide treatment is provided and potential future developments in this new drug class of selective N-type voltage-sensitive calcium-channel blockers are reviewed.
Journal ArticleDOI
Pharmacokinetics of opioids in liver disease.
TL;DR: Although glucuronidation is thought to be less affected in liver cirrhosis, the clearance of morphine was found to be decreased and oral bioavailability increased, and the disposition of a few opioids, such as fentanyl, sufent anil and remifentanil, appears to be unaffected in liver disease.
Journal ArticleDOI
Genetic predictors of the clinical response to opioid analgesics: Clinical utility and future perspectives
TL;DR: This review uses a candidate gene approach to identify possible pharmacogenetic modulators of opioid therapy, and discusses these modulators together with demonstrated genetic causes for the variability in clinical effects of opioids.